Long-term follow-up of patients from the EXCELLENT trial
Official title: A Multicentre Observational Study to Assess Long-term Outcome of Participants in the EXCELLENT Clinical Trial
Run by CellProthera · NCT06521047 · Data updated 2026-11-12
This study looks at the long-term health of patients from the EXCELLENT trial to see how well the treatments they received worked over 10 years.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 48 (estimated) |
| Sponsor | CellProthera Industry-sponsored |
| Locations | 10 sites (Mulhouse, France and 9 other locations) |
| Status | Recruiting |
| Started | July 20, 2024 |
| Main results expected | March 15, 2034 |
| Study ends | March 15, 2034 |
| Registry record updated | September 25, 2024 |
| Trial ID | NCT06521047 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates are individuals who completed the last visit in the EXCELLENT trial and are within 10 years post-randomization.
✕Probably not a fit
Patients who were randomized to the ProtheraCytes group but did not receive the product from the EXCELLENT trial will not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This observational study aims to assess the long-term clinical outcomes of patients who participated in the EXCELLENT clinical trial, specifically those randomized to either the Standard of Care or ProtheraCytes arm. Participants will be followed for a duration of 10 years to gather data on their health status and any relevant clinical events. The study does not involve any new interventions, focusing instead on collecting and analyzing existing patient data. By evaluating these long-term outcomes, the study seeks to provide insights into the effectiveness of the treatments administered during the EXCELLENT trial.
Why it matters
Potential benefit: If successful, this study could provide valuable information on the long-term effectiveness and safety of treatments for acute myocardial infarction.
How similar studies have gone: Other observational studies have successfully assessed long-term outcomes in similar patient populations, indicating that this approach is both valid and valuable.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion criteria : * Completion of the last visit in the EXCELLENT interventional clinical trial. * Participation must be within 10 years after the randomization in the EXCELLENT trial Exclusion criteria : * Patients randomized to the ProtheraCytes® group who did not receive the product of the EXCELLENT Trial are excluded. * Any other coexisting conditions that will preclude participation in the study or compromise ability to give informed consent
Where it's running
-
CHU Montpellier Arnaud-De-Villeneuve
Montpellier, France Recruiting -
Hôpital de Rangueil
Toulouse, France Recruiting -
Ghrmsa
Mulhouse, France, France Active not recruiting -
CHU DIJON Hôpital François Mitterrand 14 rue Gaffarel
Dijon, France Active not recruiting -
Institut Jacques Cartier
Massy, France Active not recruiting -
Hôpital Haut Levèque
Pessac, France Active not recruiting
Show 4 more locations
-
Ninewells Hospital & Medical School
Dundee, United Kingdom Not yet recruiting -
BIRMINGHAM, Queen Elizabeth Hospital ,Mindelsohn Way,
Edgbaston, United Kingdom Not yet recruiting -
University of Edinburgh
Edinburgh, United Kingdom Not yet recruiting -
Saint Bartholomew's Hospital W Smithfield,
London, United Kingdom Not yet recruiting
Study contacts
- Study coordinator: Aude BOLLINGER, MSc
- Email: abollinger@cellprothera.com
- Phone: +33-(3)-69-71-97-71
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Evaluating a noninvasive tissue sensor to detect cardiogenic shock earlier in heart patients
This pilot, noninvasive study tests whether the NIRSense wearable can help detect deterioration in adults with cardiogenic shock risk due to heart attack or heart failure.
-
Adenosine given before primary PCI to reduce no-reflow in STEMI patients.
See if giving intracoronary adenosine before primary PCI lowers the chance of slow flow/no-reflow in adults with STEMI.
-
Subclinical depression in people after a first heart attack (SUBDIMA25)
This project will test how common mild depressive symptoms are in adults hospitalized for a first heart attack and whether those symptoms relate to biomarkers, heart function, and recovery over the next year.
-
Long-term follow-up after Hearticellgram-AMI treatment
We will follow people who got one dose of Hearticellgram-AMI after a heart attack for up to 60 months to see if the treatment stays safe.
-
Long-term remote ischemic preconditioning after a heart attack
This trial will test whether daily brief arm blood‑flow restriction after a recent heart attack can lower the chance of major heart and brain events over the following year for people treated for acute myocardial infarction.
-
Using wearable devices to monitor heart attack patients
This study tests whether wearable devices can help monitor heart attack patients in the hospital to improve their care and predict their recovery.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.